search
Drug Discovery News
Trends
- 1
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 2AI helping scientists advance biological design in health research▼How AI is allowing scientists to advance biological design for health research: HealthLink
Scientists are increasingly using artificial intelligence to speed up biological design for health research, applying AI tools to engineer proteins, model biological systems and accelerate drug and therapy development. The approach is being highlighted as a way to cut research timelines and expand what laboratories can design, with health reporters examining how the technology is changing biomedical science and what it could mean for future treatments.
- 3Recursion Pharmaceuticals stock draws investor attention▼Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history
Recursion Pharmaceuticals (RXRX) is appearing on finance watchlists, with Yahoo Finance tracking its stock price, quotes and history. The clinical-stage biotech, which uses AI in drug discovery, is being followed by investors looking for updates on its share performance and company news.
- 4
Anthropic, the AI company behind the Claude models, is reported to be launching or operating a wet laboratory, prompting discussion about what this means for the pharmaceutical industry. The move suggests AI firms may move from software into hands-on biology and drug discovery. Commenters are weighing whether AI companies building physical lab capabilities could accelerate drug development or disrupt traditional pharma research models.